Evidence map›Paper›PMID 40943568›Full record

ArticleInternational journal of molecular sciences2025

A Study on the Efficacy and Pharmacological Mechanism of Liposome Complexes Containing STING Agonist and Anti-PD-L1 Nanobody in Inhibiting HCC.

Xiaoqing Wang, Xing Lu, Chang Liu, Hao Cheng, Xiangshi Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoqing WangDepartment of Chemistry, Fudan University, Shanghai 200433, China.ORCID 0009-0006-3097-0894
Xing LuDepartment of Chemistry, Fudan University, Shanghai 200433, China.
Chang LiuDepartment of Chemistry, Fudan University, Shanghai 200433, China.
Hao ChengDepartment of Chemistry, Fudan University, Shanghai 200433, China.
Xiangshi TanDepartment of Chemistry, Fudan University, Shanghai 200433, China.

Funding

the National Science Foundation of China 32471351
6 · The paper itself

Abstract

The low immunogenicity and immune escape are bottlenecks for effective hepatocellular carcinoma (HCC) immunotherapy. We prepared and characterized a dual-target liposome complex, XA5508, by encapsulating the STING agonist cGAMP in liposomes and conjugating an anti-PD-L1 nanobody to the liposome surface. The anti-tumor effect and pharmacological mechanism of XA5508 were investigated using an in situ HCC mouse model. XA5508 can effectively inhibit in situ HCC with the characteristics of tumor-targeted delivery and sustained release of STING agonist cGAMP. The pharmacological mechanism study indicates that XA5508 activates the STING signaling pathway, increases the cytotoxicity of CD8

Indexed as

B7-H1 AntigenCarcinoma, HepatocellularLiposomesLiver NeoplasmsMembrane ProteinsSingle-Domain AntibodiesAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansImmunotherapyMiceNucleotides, CyclicSTING ProteinTumor MicroenvironmentB7-H1 AntigenCD274 protein, humancyclic guanosine monophosphate-adenosine monophosphateLiposomesMembrane ProteinsNucleotides, CyclicSingle-Domain AntibodiesSting1 protein, mouseSTING Proteinanti-PD-L1 nanobodycGAMPhepatocellular carcinoma (HCC)nanobodySTING agonist

Identifiers

PMID40943568
PMCPMC12429036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.